Skip to search formSkip to main contentSkip to account menu

Alendronate Sodium

Known as: Alendronic Acid Monosodium Salt Trihydrate, Alendronate Monosodium Salt, Trihydrate, sodium alendronate 
The sodium salt of alendronate, a second generation bisphosphonate and synthetic analog of pyrophosphate with bone anti-resorption activity… 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (2)

AlendronateDiphosphonates
Alendronic acidAlendronic acid 35 MG Oral TabletAlendronic acid 70 MG Oral Tablet [Fosamax]

Narrower (2)

FosamaxMK-217

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2005
Highly Cited
2005
Clinical pharmacology of alendronate sodium
Clinical studies have been performed to investigate the pharmacokinetics and pharmacodynamics of alendronate, an inhibitor of… 
Highly Cited
2004
Highly Cited
2004
Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study.
Highly Cited
2003
Highly Cited
2003
Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial.
CONTEXT Therapy with individual antiresorptive agents has been shown to be effective for prevention and treatment of… 
Highly Cited
2000
Highly Cited
2000
Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group.
BACKGROUND Women with new vertebral fractures have an increased risk of back pain and functional limitation because of back pain… 
Review
2000
Review
2000
Weekly administration of alendronate: rationale and plan for clinical assessment.
Review
1998
Review
1998
Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial
Osteoporosis is characterized by low bone mass and architectural changes in bone that render the skeleton brittle and susceptible… 
Highly Cited
1997
Highly Cited
1997
The John Charnley Award. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model.
In this study the efficacy of an oral bisphosphonate therapy to inhibit wear debris mediated bone resorption was evaluated in a… 
Highly Cited
1996
Highly Cited
1996
Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis.
Highly Cited
1996
Highly Cited
1996
Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.
Highly Cited
1995
Highly Cited
1995
Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)